ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Биомаркеры нейродегенеративных заболеваний в крови: трудности на преаналитическом, аналитическом и постаналитическом этапах

Биомаркеры нейродегенеративных заболеваний в крови: трудности на преаналитическом, аналитическом и постаналитическом этапах

Авторы:
Делаби Констанс,
Леманн Сильвен

Журнал: Лабораторная служба. 2026;15(2):37-47.

DOI: 10.17116/labs20261502137

Прочитано: 410 раз

Резюме

Последние достижения в изучении сывороточных маркеров нейродегенеративных заболеваний открывают большие возможности для ранней диагностики и более эффективного мониторинга этих состояний. Однако проблемы стандартизации взятия образцов, их обработки и выдачи результатов продолжают препятствовать воспроизводимости методики, ограничивают сопоставимость между исследованиями и задерживают внедрение тестов в клиническую практику. По мере развития технологических новшеств и интеграции тестов в диагностические протоколы ожидается, что представленные биомаркеры перейдут из разряда научных показателей в сферу рутинного клинического применения, делая высокоточную медицину более доступной для людей, страдающих нейродегенеративными заболеваниями.

Ключевые слова

  • биомаркеры крови
  • клиническое внедрение
  • нейродегенеративные заболевания

Дата поступления: 08.05.2026

Дата принятия в печать: 12.05.2026

Дата публикации: 29.06.2026

Литература / References
  1. Mohaupt P, Pons ML, Vialaret J, Delaby C., Hirtz C., Lehmann S. β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer’s disease. Alzheimers Res Ther. 2022;14:179. https://doi.org/10.1186/s13195-022-01125-1
  2. Verberk IMW, Gouda M, Antwi-Berko D, et al. Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer’s disease biomarker measurement: results and consensus of the global biomarker standardization consortium. Alzheimers Dement. 2025;21:e70752. https://doi.org/10.1002/alz.70752
  3. Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7:257-262. https://doi.org/10.1016/j.jalz.2011.03.004
  4. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577-589. https://doi.org/10.1038/s41582-018-0058-z
  5. Khalil M, Teunissen CE, Lehmann S, et al. Neurofilaments as biomarkers in neurological disorders – towards clinical application. Nat Rev Neurol. 2024;20:269-287. https://doi.org/10.1038/s41582-024-00955-x
  6. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954-963. https://doi.org/10.1038/s41591-021-01382-x
  7. Lehmann S, Delaby C, Boursier G, et al. Relevance of Aβ42/40 ratio for detection of Alzheimer disease pathology in clinical routine: the PLMR scale. Front Aging Neurosci. 2018;10:138. https://doi.org/10.3389/fnagi.2018.00138
  8. Mielke MM, Anderson M, Ashford JW, et al. Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement. 2024;20:8216-8224. https://doi.org/10.1002/alz.14184
  9. Schöll M, Verberk IMW, Del Campo M, et al. Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease. Lancet Healthy Longev. 2024;5:100630. https://doi.org/10.1016/j.lanhl.2024.07.013
  10. Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. 2020;217:e20200861. https://doi.org/10.1084/jem.20200861
  11. Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28:1398-1405. https://doi.org/10.1038/s41591-022-01822-2
  12. Gonzalez-Ortiz F, Turton M, Kac PR, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration. Brain. 2023;146:1152-1165. https://doi.org/10.1093/brain/awac407
  13. Chatterjee P, Pedrini S, Doecke JD, et al. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer’s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023;19:1117-1134. https://doi.org/10.1002/alz.12724
  14. Benussi A, Karikari TK, Ashton N, et al. Diagnostic and prognostic value of serum NfL and p-Tau 181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91:960-967. https://doi.org/10.1136/jnnp-2020-323487
  15. Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8:14798. https://doi.org/10.1038/s41598-018-33158-8
  16. Benussi A, Ashton NJ, Karikari TK, et al. Serum glial fibrillary acidic protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration. JAD. 2020;77:1129-1141. https://doi.org/10.3233/jad-200608
  17. Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021;144:3505-3516. https://doi.org/10.1093/brain/awab223
  18. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921-923. https://doi.org/10.1126/science.8346443
  19. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106-118. https://doi.org/10.1038/nrneurol.2012.263
  20. Meeter LHH, Patzke H, Loewen G, et al. Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. Dement Geriatr Cogn Dis Extra. 2016;6:330-340. https://doi.org/10.1159/000447738
  21. Cosma C, Talli I, Pangrazzi E, et al. Progranulin measurement with a new automated method: a step forward in the diagnostic approach to neurodegenerative disorders. Clin Chem Lab Med. 2025;63:1118-1123. https://doi.org/10.1515/cclm-2024-1143
  22. Dubois B. The emergence of a new conceptual framework for Alzheimer’s disease. J Alzheimers Dis. 2018;62:1059-1066. https://doi.org/10.3233/jad-170536
  23. Sarazin M, de Souza LC, Lehéricy S, Dubois B. Clinical and research diagnostic criteria for Alzheimer’s disease. Neuroimaging Clin N Am. 2012;22:23-32. https://doi.org/10.1016/j.nic.2011.11.004
  24. Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12:3555. https://doi.org/10.1038/s41467-021-23746-0
  25. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26:379-386. https://doi.org/10.1038/s41591-020-0755-1
  26. Chouliaras L, Thomas A, Malpetti M, et al. Differential levels of plasma biomarkers of neurodegeneration in lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93:651-658. https://doi.org/10.1136/jnnp-2021-327788
  27. Delaby C, Alcolea D, Hirtz C, et al. Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. J Neural Transm. 2022;129:231-237. https://doi.org/10.1007/s00702-022-02474-9
  28. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;28. https://doi.org/10.1001/jama.2020.12134
  29. Ashton NJ, Pascoal TA, Karikar TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol [Internet]. 2021;14. https://doi.org/10.1007/s00401-021-02275-6
  30. Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26:429-442.
  31. Leuzy A, Janelidze S, Mattsson-Carlgren N, et al. Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays. Neurology. 2021;97:e1681-1694. https://doi.org/10.1212/wnl.0000000000012727
  32. Nafash MN, Svirsky SE, Zeng X, et al. Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay. medRxiv. 2025;21. https://doi.org/10.1101/2025.07.21.25331193
  33. Clemmensen FK, Gonzalez-Ortiz F, Gramkow MH, et al. The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients. Alzheimers Dement (NY). 2025;11:e70143. https://doi.org/10.1002/trc2.70143
  34. Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer’s disease neuroimaging initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557-566. https://doi.org/10.1001/jamaneurol.2016.6117
  35. van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18:1103-1111. https://doi.org/10.1016/s1474-4422(19)30354-0
  36. Ashton N, Janelidze S, Khleifat AA, et al. Diagnostic value of plasma neurofilament light: a multicentre validation study [internet]. In: Review; 2020. https://doi.org/10.21203/rs.3.rs-63386/v1
  37. Al Shweiki MR, Steinacker P, Oeckl P, et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J Psychiatr Res. 2019;113:137-140. https://doi.org/10.1016/j.jpsychires.2019.03.019
  38. Light V, Jones SL, Rahme E, et al. Clinical accuracy of serum neurofilament light to differentiate frontotemporal dementia from primary psychiatric disorders is age-dependent. Am J Geriatr Psychiatry. 2024;32:988-1001. https://doi.org/10.1016/j.jagp.2024.03.008
  39. Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130-139. https://doi.org/10.1002/ana.25276
  40. Mondesert E, Delaby C, De La Cruz E, et al. Comparative performances of 4 serum NfL assays, pTau181, and GFAP in patients with amyotrophic lateral sclerosis. Neurology. 2025;104:e213400. https://doi.org/10.1212/wnl.0000000000213400
  41. Lehmann S, Gabelle A, Duchiron M, et al. Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis. EBioMedicine. 2025;10. Volume 117; 105805. https://doi.org/10.1101/2024.12.07.24318640
  42. Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:251-257. https://doi.org/10.1111/ene.14063
  43. Lie IA, Kaçar S, Wesnes K, et al. Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatry. 2022;93:849-857. https://doi.org/10.1136/jnnp-2021-328568
  44. Buchmann A, Pirpamer L, Pinter D, et al. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. Eur J Neurol. 2023;30:1389-1399. https://doi.org/10.1111/ene.15742
  45. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870-881. https://doi.org/10.1136/jnnp-2018-320106
  46. Delaby C, Alcolea D, Carmona-Iragui M, et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Scientific Report. 2020;10, 9161. https://doi.org/10.1038/s41598-020-66090-x
  47. Chatterjee P, Pedrini S, Stoops E, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl Psychiatry. 2021;11:27. https://doi.org/10.1038/s41398-020-01137-1
  48. Oeckl P, Halbgebauer S, Anderl-Straub S, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67:481-488. https://doi.org/10.3233/jad-180325
  49. Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: results from the standardization of Alzheimer’s blood biomarkers (SABB) working group. Alzheimers Dement. 2022;18:1484-1497. https://doi.org/10.1002/alz.12510
  50. Kurz C, Stöckl L, Schrurs I, et al. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer’s disease. J Neurochem. 2023;165:95-105. https://doi.org/10.1111/jnc.15757
  51. Gonzalez-Ortiz F, Dias A, Turton M, et al. Preanalytical stability of plasma/serum brain-derived tau. Alzheimers Dement. 2023;19:4764-4770. https://doi.org/10.1002/alz.13156
  52. Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and simoa. Clin Chem Lab Med. 2016;54:1655-1661. https://doi.org/10.1515/cclm-2015-1195
  53. Wu Z, Mielke MM, Murray AM, et al. The impact of pre-analytical factors on plasma biomarkers for Alzheimer’s disease: the ASPREE healthy ageing biobank. J Prev Alzheimers Dis. 2025;12:100058. https://doi.org/10.1016/j.tjpad.2025.100058
  54. Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375. https://doi.org/10.1001/jamaneurol.2021.3180
  55. Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841-849. https://doi.org/10.1016/j.jalz.2017.06.2266
  56. West T, Kirmess KM, Meyer MR, et al. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener. 2021;16:30. https://doi.org/10.1186/s13024-021-00451-6
  57. Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. 2022;awac333. https://doi.org/10.1093/brain/awac333
  58. Ashton NJ, Puig-Pijoan A, Milà-Alomà M, et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2023;19:1913-1924. https://doi.org/10.1002/alz.12841
  59. Eastwood SM, Meyer MR, Kirmess KM, et al. PrecivityAD2TM blood test: analytical validation of an LC-MS/MS assay for quantifying plasma Phospho-tau217 and Non-Phospho-tau217 peptide concentrations that are used with plasma Amyloid-β42/40 in a multianalyte assay with algorithmic analysis for detecting brain amyloid pathology. Diagnostics. 2024;14:1739. https://doi.org/10.3390/diagnostics14161739
  60. Benedet AL, Milà-Alomà M, Vrillon A, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78:1471. https://doi.org/10.1001/jamaneurol.2021.3671
  61. Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554:249-254. https://doi.org/10.1038/nature25456
  62. Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857-870. https://doi.org/10.1002/ana.24954
  63. Bornhorst JA, Lundgreen CS, Weigand SD, et al. Quantitative assessment of the effect of chronic kidney disease on plasma P-Tau217 concentrations. Neurology. 2025;104:e210287. https://doi.org/10.1212/wnl.0000000000210287
  64. Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain. 2020;143:3234-3241. https://doi.org/10.1093/brain/awaa286
  65. Delaby C, Ladang A, Martinez-Yriarte J, et al. Clinical use and reporting of neurofilament quantification in neurological disorders: a global overview. Alzheimers Dement. 2025;21:e70343. https://doi.org/10.1002/alz.70343
  66. Noda K, Lim Y, Goto R, Sengoku S, Kodama K. Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer’s disease diagnosis. Drug Discov Today. 2024;29:103911. https://doi.org/10.1016/j.drudis.2024.103911
slide-cover
slide-cover
slide-cover

Рекомендуем статьи по данной теме:

Двунаправленные связи между депривацией сна и развитием нейродегенеративных заболеваний.Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2026;126(5-2):74-80

Болезнь Герстманна—Штраусслера—Шейнкера.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(4):143-149

Частота встречаемости нутритивной недостаточности у пациентов с болезнью Альцгеймера и болезнью Паркинсона.Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(12):113-119

Новый взгляд на биомаркеры крови у пациентов с болезнью Альцгеймера.Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(12):7-13

Нейровоспалительные и нейродегенеративные аспекты болезни Паркинсона.Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(3):102-111

Нутритивная поддержка пациентов с нейродегенеративными заболеваниями на амбулаторном приеме невролога.Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(1):76-83

Коморбидные тревожные расстройства у пациентов с неврологической патологией: современное состояние проблемы и место этифоксина в стратегии лечения.Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(12):126-136

Ассоциация воспаления и синдрома хронической усталости при болезни Паркинсона.Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(9):79-87

Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29

  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12

  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru

  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026